Your browser doesn't support javascript.
loading
Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids.
Hu, Huimin; Wang, Chen; Tao, Rui; Liu, Bohan; Peng, Dazhao; Chen, Yankun; Zhang, Wei.
Affiliation
  • Hu H; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
  • Wang C; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Tao R; Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China.
  • Liu B; China National Clinical Research Center for Neurological Diseases, Beijing, China.
  • Peng D; Chinese Glioma Genome Atlas Network (CGGA), Beijing, China.
  • Chen Y; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
  • Zhang W; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
CNS Neurosci Ther ; 30(6): e14822, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38923860
ABSTRACT

INTRODUCTION:

Despite the extensive neurological symptoms induced by COVID-19 and the identification of SARS-CoV-2 in post-mortem brain samples from COVID-19 patients months after death, the precise mechanisms of SARS-CoV-2 invasion into the central nervous system remain unclear due to the lack of research models.

METHODS:

We collected glioma tissue samples from glioma patients who had a recent history of COVID-19 and examined the presence of the SARS-CoV-2 spike protein. Subsequently, spatial transcriptomic analyses were conducted on normal brain tissues, glioma tissues, and glioma tissues from glioma patients with recent COVID-19 history. Additionally, single-cell sequencing data from both glioma tissues and glioma organoids were collected and analyzed. Glioma organoids were utilized to evaluate the efficacy of potential COVID-19 blocking agents.

RESULTS:

Glioma tissues from glioma patients with recent COVID-19 history exhibited the presence of the SARS-CoV-2 spike protein. Differences between glioma tissues from glioma patients who had a recent history of COVID-19 and healthy brain tissues primarily manifested in neuronal cells. Notably, neuronal cells within glioma tissues of COVID-19 history demonstrated heightened susceptibility to Alzheimer's disease, depression, and synaptic dysfunction, indicative of neuronal aberrations. Expressions of SARS-CoV-2 entry factors were confirmed in both glioma tissues and glioma organoids. Moreover, glioma organoids were susceptible to pseudo-SARS-CoV-2 infection and the infections could be partly blocked by the potential COVID-19 drugs.

CONCLUSIONS:

Gliomas had inherent traits that render them susceptible to SARS-CoV-2 infection, leading to their representability of COVID-19 neurological symptoms. This established a biological foundation for the rationality and feasibility of utilization of glioma organoids as research and blocking drug testing model in SARS-CoV-2 infection within the central nervous system.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Organoids / SARS-CoV-2 / COVID-19 / Glioma Limits: Female / Humans / Male / Middle aged Language: En Journal: CNS Neurosci Ther Journal subject: NEUROLOGIA / TERAPEUTICA Year: 2024 Document type: Article Affiliation country: Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Organoids / SARS-CoV-2 / COVID-19 / Glioma Limits: Female / Humans / Male / Middle aged Language: En Journal: CNS Neurosci Ther Journal subject: NEUROLOGIA / TERAPEUTICA Year: 2024 Document type: Article Affiliation country: Publication country: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM